Traws Pharma, Inc. insider trading

Every open-market purchase and sale by Traws Pharma, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $998,207 1 trade by 1 insider 3 months later: median −45.5% (−52.7% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Traws Pharma, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Traws Pharma, Inc.’s insiders pay?

From November 18, 2013 to April 28, 2026, 17 insiders reported 35 open-market purchases and 10 sales not made under a pre-set plan in Traws Pharma, Inc. Twelve months after each purchase was reported, the shares were −83.7% against the S&P 500 on average (median −83.2%), over 8 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 19, 2013 into $2,265 by November 2, 2026, −10.9% a year. It held shares 10% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $15,663 (+3.5% a year), and held throughout $52,568 (+13.7%).

Copying Traws Pharma, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Traws Pharma, Inc.'s insiders from November 19, 2013, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 10% of the time.

Traws Pharma, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Hoffman Michael B	Director	5	−84.8% (5)	0%	2	—	August 31, 2020
Tyndall Capital Partners L P	10% owner	2	—	—	5	—	September 26, 2019
Marino James J	Director	6	—	—	0	—	September 28, 2021
Fruchtman Steven M	President, Chief Executive Off	4	—	—	0	—	September 28, 2021
Reddy E Premkumar	Director	3	−85.6% (1)	0%	1	—	August 31, 2020
Oler Abraham N.	SVP Corp Dev & Gen Counsel	3	—	—	0	—	September 29, 2021
Guerin Mark Patrick	Chief Financial Officer	2	—	—	0	—	February 17, 2021
Kumar Ramesh	President and CEO	2	−79.8% (1)	0%	0	—	April 28, 2017
Shoemaker Mary Teresa	Director	2	—	—	0	—	February 17, 2021
683 Capital Management, LLC	10% owner	1	—	—	0	—	May 1, 2018
683 Capital Partners, LP	10% owner	1	—	—	0	—	February 12, 2018
Bienen Henry S	Director	1	−79.8% (1)	0%	0	—	November 18, 2013
Boyd Steven	10% owner	0	—	—	1	—	September 25, 2019
Gelder Mark S. Md	Chief Medical Officer	1	—	—	0	—	September 29, 2021
Mehta Viren	Director	1	—	—	0	—	November 27, 2019
Orbimed Capital Gp VIII LLC	10% owner	1	—	—	0	—	April 28, 2026
Zweiman Ari	10% owner	0	—	—	1	—	September 20, 2019

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Traws Pharma, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Traws Pharma, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −77.8% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
November 29, 2013	5 buying	−48.2%	−77.8%	−86.6%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Traws Pharma, Inc. · Funds · Politicians